Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906) | Zendy

Jochen Rößler | Zendy; Schönherr | Zendy; Lewrick | Zendy; Süss | Zendy; Francese | Zendy; Karine Scherzinger-Laude | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906)

Author(s) -

Jochen Rößler,

Schönherr,

Lewrick,

Süss,

Francese,

Karine Scherzinger-Laude

Publication year - 2013

Publication title -

international journal of nanomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.245

H-Index - 128

eISSN - 1178-2013

pISSN - 1176-9114

DOI - 10.2147/ijn.s44025

Subject(s) - rhabdomyosarcoma , neuroblastoma , liposome , in vivo , medicine , cancer research , pharmacology , in vitro , toxicity , cell culture , chemistry , biology , pathology , sarcoma , biochemistry , genetics , microbiology and biotechnology

Patupilone (EPO906) is a microtubule stabilizer with a potent antitumor effect. Integrin αVβ3-binding (RGD) liposomes were loaded with EPO906, and their antitumor efficacy was evaluated in two pediatric tumor models, ie, neuroblastoma and rhabdomyosarcoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research